Are you living with Crohn's Disease?

The GALAXI Study - A clinical trial to assess the safety and effectiveness of a new drug for Crohn’s Disease

We are looking for people with Crohn's Disease to participate in a study to determine the safety and effictiveness of a new study medication, guselkumab.

Guselkumab is made in the laboratory and is a fully human monoclonal antibody. An antibody is something that targets and kills foreign objects in the body - in this case, small proteins that are released by cells and affect the behaviour of other cells. This antibody, guselkumab, recognizes and blocks a specific small protein, IL-23, which is important in immune and inflammatory processes.

Anticipated date that enrolment will close: 31 December 2022

Who can take part

Inclusion

  • Crohn’s Disease for at least 3 months

Exclusion

  • Symptomatic stricture
  • Current abscess
  • Bowel resection in last 6 months
  • Draining Stoma or Ostomy

What is involved for you

Medical History, Physical Exam, Electrocardiogram (ECG), Weight, Height, Blood Pressure, Pulse, Heart Rate, Health Questionnaires, Blood Samples, Urine Test, Colonoscopy with biopsy collection, Stool Tests

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4

For more information

Quote reference number
2018.057
Zafirah Khan
(03) 9342 8995
Nicole Tresize
(03) 9342 8411